Conjunctival structure of glaucomatous eyes treated with anti-glaucoma eye drops: a cross-sectional study using anterior segment optical coherence tomography

Table 4 The univariate and general linear mixed model (GLMM) analyses on the Tenon’s capsule/sclera preservation rate

a. The effects of background characteristics
	Univariable analysis		Multiple analysis 1
	β	p-value	Β	p-value	VIF
Sex (male vs. female)	−0.008	0.886	− 0.027	0.384	1.08
Age (years)	−0.004	0.941	0.027	0.354	1.06
Number of anti-glaucoma eye drops	−0.624	< 0.001	− 0.408	< 0.001	1.74
Duration of administration (months)	−0.653	< 0.001	−0.374	< 0.001	1.72
b. The effects of anti-glaucoma eye drops
	Univariable analysis		Multiple analysis 2		Multiple analysis 3
	β	p-value	β	p-value	β	p-value	VIF
Prostaglandin analogs	−0.569	< 0.001	−0.193	< 0.001	−0.191	< 0.001	1.72
α2-receptor agonist	−0.352	< 0.001	0.186	< 0.001	0.146	0.001	1.57
Rho kinase inhibitor	−0.196	< 0.001	− 0.045	0.147
The fixed combination of β-blockers/CAIs	−0.435	< 0.001	−0.069	0.102
The fixed combination of β-blockers/prostaglandin analogs	−0.321	< 0.001	− 0.053	0.136	−0.091	0.008	1.33
β-blockers	−0.149	0.010	−0.004	0.907
CAIs	−0.234	< 0.001	0.070	0.052

Multiple analysis 1, multiple GLMM analysis with the thickness of the preservation rate and with background characteristics; Multiple analysis 2, multiple GLMM analysis with the preservation rate and with the eye drops after adjusted for confounding factor (number of anti-glaucoma eye drops and duration of administration).; Multiple analysis 3, the stepwise method for variable selection
CAI carbonic anhydrase inhibitors, VIF variance inflation factor

ISSN: 1471-2415